Trial Profile

Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone decanoate (Primary) ; Dexamethasone; Docetaxel; Prednisone; Steroids
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Sponsors Astellas Pharma; Propella Therapeutics

Most Recent Events

01 Oct 2025 According to an Astellas Pharma media release, data from this trial will be featured in an ESMO Presidential Symposium.
25 Sep 2025 Planned primary completion date changed from 31 Aug 2025 to 31 May 2029.
13 Dec 2024 Planned End Date changed from 30 Apr 2025 to 31 May 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com